LSTA Q4 2024 Earnings — Lisata Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

LSTALisata Therapeutics, Inc.

$44M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M

Gross Profit

$1M100.0% margin

Operating Income

-$5M-494.9% margin

Net Income

-$5M-461.0% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$871,763

Balance Sheet

Total Assets

$35M

Total Liabilities

$6M

Stockholders' Equity

$30M

Cash & Equivalents

$16M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$0	—
Gross Profit	$1M	$0	—
Operating Income	-$5M	-$6M	+17.9%
Net Income	-$5M	-$5M	+14.1%